Novartis news

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure

Novartis investigational bronchodilator QAB149 improves lung function and reduces breathlessness compared to tiotropium in patients with COPD

Novartis MF59® adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials

Novartis hosts scientific symposium in Philippines to review research approaches, clinical management, and growing presence of Dengue

Novartis receives approval in EU for Xolair® to treat children age 6 to 11 years suffering from severe persistent allergic asthma

Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp)

Results in The New England Journal of Medicine confirm Novartis drug Femara® is superior to tamoxifen after breast cancer surgery

US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease

Sandoz launches first generic version of Prograf® capsules